Xtalpi Holdings Limited · HKEX:2228
Xtalpi — Investor Presentation (2025)
29 slides from Xtalpi's investor presentation, Mar 31, 2025
Slide 1: 2024 Investor Presentation
XtalPi 2228.HK 2024 Investor Presentation 1
Slide 2: Cautionary Note
2228.HK Cautionary Note This presentation may contain forward-looking statements relating to the forecasts, targets, outlook, estimates of financial performance, opportunities, challenges, business developments, business plans and growth strategies of XtalPi Holdings Limited (the “Company” or “XtalP
Slide 3: Building the ASI infrastructure for the life sciences and materials industries
Building the ASI infrastructure for the life sciences and materials industries 10101110001100011 01001100110111001011 101011101010111001 10101110001100011 01001100110111001011 101011101010111001 Quantum Artificial Robots Computing physics Intelligence Power 3
Slide 4: Global locations, employees, robotic lab and computing power
Shenzhen, China Shanghai, China Beijing, China Boston, USA Shenzhen International Shanghai Zhangjiang Beijing 100 Chestnut Biomedical Industrial Park Innovation Park Zhongguancun 800+ Over 10,000m2 500+ Employees Robotic Laboratory Space R&D Personnel 200+ 1M+ Cores Global Computing 160+ Models Pate
Slide 5: The first 18C stock listed on HKEX
The first 18C stock listed on HKEX (XtalPi 2228.HK) June 2024 5 5
Slide 6: An Innovative Force Widely Recognized Globally
An Innovative Force Widely Recognized Globally Top 10 pharma companies by 2023 revenue and their AI ARK Invest—BIG IDEAS 2025 drug discovery activities Forbes—The Chinese MIT Physicist Uses AI To Find New Drugs, Next Up: Solar Panels And EV Batteries Largest weighting in the GS China AI Healthcare T
Slide 7: Extensive Cooperation with Top Pharmaceutical and Material Sciences Companies
Extensive Cooperation with Top Pharmaceutical and Material Sciences Companies, Research Giants and Government Agencies Continuing our in-depth AIDD Signed a US$250 million AI drug Working with MIT to jointly build the Strategic partnership with development cooperation with discovery research agreeme
Slide 8: Highly-Flexible and High-Precision Robotics
Highly-Flexible and High-Precision Robotics Traditional Chinese Medicine: Hengqin Lab in Petrochemical Industry: Shanghai Research Pharma Institute of Sinopec Guangdong Automated Compound Library Catalyst Screening The Modernizations Platform for TCM New Energy: The State Key Laboratory R&D Institut
Slide 9: Highly-Flexible, High-Precision Robotic Scientists
High Data Quality Highly-Flexible, High-Precision Robotic Scientists High Efficiency Evolution Scalability 24/7 Confidential Copyright © 9 2024
Slide 10: Business Update
3S xtal?i 2024 Business Update
Slide 11: AI + Robotics Reshapes the R&D Paradigm
AI + Robotics Reshapes the R&D Paradigm and Ushers in the Era of Intelligent Drug and Material Development Opening the Era of Intelligent Molecular R&D • Data Moat Construction: Our automated robotic laboratory can cover Human-designed Molecules AI-designed Molecules over 80% of common medicinal che
Slide 12: AI Reaction Prediction Capabilities: AI Models Outperform Human Experts
2228.HK AI Reaction Prediction Capabilities: AI Models Outperform Human Experts, Pioneering a Transformative Era AI Prediction Models Successful Reaction Prediction Failed Reaction Prediction AI model significantly outperforms the AI model significantly outperforms both second group of chemists grou
Slide 13: AI Agents Improve R&D Efficiency
2228.HK AI Agents Improve R&D Efficiency Research Agent Analytical Agent Quality Agent Base Large Language Model Drug Discovery Predictive Chemistry ETL and Data Spectral Analysis Robotic Controlling AI Models AI Models Management Tools AI Model Tools End-to-End Digitized System Automated Robotic La
Slide 14: Latest Progress in Drug Development
2228.HK Latest Progress in Drug Development More than 300 global partners AI for Science platform empowering incubation Recognized by globally-leading Pipeline entering clinical stage pharmaceutical companies Signet Pipeline Stage Indications × Leading biotech × Leading biopharma IND Diffuse Gastric
Slide 15: Continuing to Invest in Cutting-Edge Therapies
2228.HK Continuing to Invest in Cutting-Edge Therapies A breakthrough was made in collaboration with Leman, the first patient with systemic lupus The tumor vaccine project in collaboration with Established an AI peptide R&D platform with a erythematosus was dosed with the a life science company was
Slide 16: XtalFold: World-Leading Protein Complex Prediction Platform
2228.HK XtalFold : World-Leading Protein Complex Prediction Platform, Receives global recognition from leading pharmaceutical companies XtalFold Antibody Drug Discovery Platform Authorized External Users Infinite Possibilities for Input Output Downstream Applications Drugs & Biomaterials Infectious
Slide 17: Intelligent Automated Robotic Solutions Open Markets Globally
Intelligent Automated Robotic Solutions Open Markets Globally UAE Guangzhou University of Chinese Medicine Hengqin Laboratory The first automated modern R&D laboratory The Modernizations Platform for TCM for traditional medicines in the Middle East https://www.pharmaceutical-technology.com/....... J
Slide 18: Top Placement at the Global Material Structure Prediction Competition
2228.HK Top Placement at the Global Material Structure Prediction Competition; Expanding Application Exploration Throughout the New Materials Industry • 28 international teams participated, challenged with predicting XtalPi was a top placer at the experimental polymorphs and their relative stability
Slide 19: AI Empowering Industries Globally
2228.HK AI Empowering Industries Globally A New Generation of Industry-Specific Scientific Research Infrastructure New Agriculture Materials AI Drug Consumer Development Goods 19 Confidential Copyright © 2025
Slide 20: Robot scientist cluster tailored for AI for Science
A highly flexible and high- precision robot scientist cluster tailored for AI for Science Vertical AI and proprietary data building industry-specific "artificial super intelligence" Confidential Copyright © 20 2024
Slide 21: Future AI-Powered Molecules Boost Materials, Agricultural, and Consumer Goods
2228.HK Future AI-Powered Molecules Boost Materials, Agricultural, and Consumer Goods Future Future Future Materials Agriculture Consumer Goods Sinopec Research Institute GCL Group Fangda Carbon Shenzhen Yanyi New Materials Shougang Vegetable MIIT Catalysts New Energy Materials Carbon-Based Material
Slide 22: Financial Results
3S xtal?i 2024 Financial Results
Slide 23: 2024 Financial Highlights
2024 Financial Highlights In 2024，comparing to 2023, the Company’s revenue increased by 53%，the adjusted net loss narrowed by 13%，and the monthly average cash burn decreased by 23% RMB mn 2024 YOY 2023 Revenue 266 53 % 174 R&D Expenses 418 -13 % 481 Adjusted Net Loss -457 -13 % -522 Monthly Average
Slide 24: Strong Revenue Growth with Expanding Customer Base
Strong Revenue Growth with Expanding Customer Base Total Revenue High-Quality Customer Base 2H 2024 YOY +73% 300 Customer base expands steadily 266 YOY 280+ +53% 250 200 174 187 133 150 120 100 63 75 50 0 2021 2022 2023 2024 2021 2022 2023 2024 RMB mn Confidential Copyright © 24 2025
Slide 25: Revenue Breakdown by Geography and Business Segment
Revenue Breakdown by Geography and Business Segment Revenue by Geographical Location (%) Revenue by Business Segment (%) Mainland China United States Others Drug Discovery Solutions Intelligent Robotics Solutions 2023 2024 2023 2024 15% 13% 50% 39% 55% 50% 57% 61% 30% 30% In 2024, the company's comp
Slide 26: Operational Expenses
Operational Expenses R&D Expenses G&A Expenses Employee Benefit Expenses Others Others SBC Listing Expenses D&A RMB mn RMB mn 480,663 358,952 43 207 30 46 181 21 64 97 274 237 181 232 2023 2024 2023 2024 ETR 276% 157% ETR 170% 157% S&M Expenses Contract Fulfillment Costs RMB mn Employee Benefit Expe
Slide 27: Improved Operating Results - Narrowed Adjusted Net Loss
Improved Operating Results - Narrowed Adjusted Net Loss Adjusted Net Loss (Non-IFRS) RMB mn 2023 2024 -457 Adjusted net loss -522 narrowed by 13% YOY Confidential Copyright © 27 2025
Slide 28: Cash Burn and Cash Balance
Cash Burn and Cash Balance Monthly Average Cash Burn Cash Balance RMB mn RMB mn Financial Assets at FVTPL（Current） Restricted Cash Term Deposit Cash and Cash Equivalents YOY +10% 3,123 2,848 YOY -23% 863 1,786 62 1,272 170 48 1,166 711 2023 2024 2023 2024 Confidential Copyright © 28 2025
Slide 29: Q&A Thanks!
Q&A Thanks! Confidential Copyright © 29 2025